Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Weighs Use of Medical Bill Database for 4 Times Yearly Price Review: Nakayama
February 10, 2017
- MHLW Councilor Cites Cancer Meds for Conditional Early Approval Scheme
February 10, 2017
- MHLW Advisory Committee Backs Shionogi’s OIC Drug
February 10, 2017
- Post-Marketing Conditions Under “Conditional Early Approval System” Remain Unclear: MHLW Councilor Kazuhiko Mori
February 10, 2017
- 2nd Batch of Sakigake Designation Slated for Spring
February 9, 2017
- Chuikyo Panel to Draw Conclusion by Summer for FY2018 Rollout of Cost-Effective Assessment Scheme
February 9, 2017
- Bill Payers, Doctors in Skirmish over Drug Price Survey for Gap-Year Revisions: Chuikyo
February 9, 2017
- Chuikyo OKs Optimal Use Guidelines for Opdivo and Keytruda, Due Out Feb. 14
February 9, 2017
- PMDA to Delay Planned Staff Increase for Financial Reasons, Pace of Increase Has Slowed Down
February 9, 2017
- Keytruda Gets Same Daily Price as Opdivo; Chuikyo OKs Batch of Drugs for Feb. 15 Listing
February 8, 2017
- MHLW Notifies of Package Insert Changes for Iguratimod
February 8, 2017
- Sanofi’s VEGF Inhibitor Clears MHLW Advisory Panel for Colorectal Cancer
February 6, 2017
- MHLW Will Strictly Respond to Violations, Shiozaki Says on Fake Harvoni Issue
February 6, 2017
- MHLW Wraps Up Probe into Fake Harvoni after Distribution Routes “Most Likely” Identified
February 2, 2017
- MHLW to Set Up Committee on Pharmaceutical and Medical Device Regulation at Health Sciences Council
February 2, 2017
- MHLW to Actively Recommend Japanese Encephalitis Vaccine for Children Turning 18
February 2, 2017
- MHLW Pins Down Distribution Routes for Harvoni Counterfeits; Composition of Fake Pills Identified
February 1, 2017
- MHLW, Pharma Industry Officials Agree on Conditional Early Approval System
January 31, 2017
- Shiozaki Calls for Enactment of Clinical Research Bill ASAP
January 30, 2017
- MHLW Committee to Discuss Shionogi’s OIC Drug on Feb. 9
January 27, 2017
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…